Irkutsk, Irkutsk region, Russian Federation
Irkutsk, Irkutsk region, Russian Federation
Ulan-Ude, Ulan-Ude, Russian Federation
Saharnyy diabet priobretaet masshtaby epidemii. Nablyudaetsya rost chisla bol'nyh ishemicheskoy bolezn'yu serdca, stradayuschih saharnym diabetom 2-go tipa. Pri nalichii saharnogo diabeta usugublyaetsya techenie ishemicheskoy bolezni serdca v vidu progressirovaniya ateroskleroza. V razvitii ateroskleroza otmechaetsya rol' citokinov, kotorye yavlyayutsya otrazheniem mestnogo i sistemnogo vospaleniya. Insulinorezistentnost', giperfibrinogenemiya, dislipidemiiya u bol'nyh saharnym diabetom usilivayut risk neblagopriyatnyh ishodov ishemicheskoy bolezni serdca.
saharnyy diabet 2-go tipa, ishemicheskaya bolezn' serdca, disfunkciya endoteliya, citokiny
1. Bardymova TP, Kolesnikova LI, Petrova VA. (2005). Lipid peroxidation and antioxidation system in patients with type 2 diabetes mellitus [Perekisnoe okislenie lipidov i antioksidantnaya sistema u bol’nykh sakharnym diabetom 2-go tipa]. Bulleten’ Vostocno-Sibirskogo naucnogo centra, (6), 11-14.
2. Goryushkina OA, Vasilyeva EM. (2013). Antioxidant therapy in the correction of oxidative stress in the patients with coronary heart disease and type 2 diabetes mellitus [Antioksidantnaya terapiya v korrektsii oksidativnogo stressa u bol’nykh ishemicheskoy bolezn’yu serdtsa s sakharnym diabetom 2-go tipa]. Vestnik novykh meditsinskikh tekhnologiy, (2), 156-158.
3. Gracheva SA, Klefortova II, Shamкhalova MS. (2015). Prevalence of combined atherosclerotic vascular lesions in patients with diabetes mellitus [Rasprostranennost’ sochetannogo ateroskleroticheskogo porazheniya sosudov u bol’nykh sakharnym diabetom]. Sakharnyy diabet, (1), 49-55.
4. Dedov II, Shestakova MV, Vikulova OK. (2015). National register of diabetes mellitus in Russian Federation: status on 2014 [Gosudarstvennyy registr sakharnogo dia beta v Rossiyskoy Federatsii: status 2014 g. i perspektivy razvitiya]. Sakharnyy diabet, (3), 5-23.
5. Dontsov AV, Vasil’eva LV. (2016). Insulin resistance associated with metabolic syndrome as an indicator of cardiovascular risk [Insulinorezistentnost’ pri metabolicheskom sindrome kak pokazatel’ serdechno-sosudistogo riska]. Klinicheskaya meditsina, (3), 189-193.
6. Doskina EV. (2010). Causes behind the failure to manage patients with type 2 diabetes mellitus. The role of postprandial glycemia [Prichiny neudach v kompensatsii patsientov s sakharnym diabetom 2-go tipa. Rol’ postprandial’noy glikemii]. Sakharnyy diabet, (1), 129-132.
7. Zakirova NE, Khafizov NK, Karamova IM, Zakirova AN, Oganov RG. (2007). Immunological reaction in coronary heart disease [Immunovospalitel’nye reaktsii pri ishemicheskoy bolezni serdtsa]. Ratsional’naya farmakoterapiya v kardiologii, (2), 16-19.
8. Litvinova LS, Kiriyenkova YV, Aksyonova NN, Gazatova ND, Zatolokin PA. (2012). Features of cellular immunity and cytokine repertoire in patients with metabolic syndrome [Osobennosti kletochnogo immuniteta i tsitokinovogo repertuara u patsientov s metabolicheskim sindromom]. Byulleten’ sibirskoy meditsiny, (3), 53-58.
9. Dedov II, Shestakova MV (ed.). (2016). Type 2 diabetes mellitus: from theory to practice [Sakharnyy diabet 2-go tipa: ot teorii k praktike]. Moskva, 571 p.
10. Shvarts V. (2009). Inflammation of adipose tissue. Part 2. Pathogenic role at type 2 diabetes mellitus [Vospalenie zhirovoy tkani. Chast’ 2. Patogeneticheskaya rol’ pri sakharnom diabete 2-go tipa]. Problemy endokrinologii, (5), 43-48.
11. Shestakova МV, Chazova IE, Shestakova EA. (2016). Russian multicentre screening program for revealing undiagnosed type 2 diabetes mellitus in patients with cardiovascular disease [Rossiyskoe mnogotsentrovoe skriningovoe issledovanie po vyyavleniyu nediagnostirovannogo sakharnogo diabeta 2-go tipa u patsientov s serdechno-sosudistoy patologiey]. Sakharnyy diabet, (1), 24-29.
12. Kolesnikova LI (ed.). (2008). Essential hypertension and genes of the renin angiotensin system [Essentsial’naya arterial’naya gipertenziya i geny reninangiotenzinovoy sistemy]. Novosibirsk, 108 p.
13. Abbatecola AM, Paolisso G, Sinclair AJ. (2015). Treating diabetes mellitus in older and oldest old people. Curr. Pharm. Des., 21, 1665-1671.
14. Amar J, Fauvel J, Drouet L, Ruidavets JB, Perret B, Chamontin B, Boccalon H, Ferrieres J. (2006). Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J. Hypertens., 6, 1083-1088.
15. Antoniades C, Tousoulis D, Tountas C, Tentolouris C, Toutouza M, Vasiliadou C, Tsioufis C, Toutouzas P, Stefanadis C. (2004). Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet. Med., 6, 552-558.
16. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, Parker N. (2004). Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic. Biol. Med., 37, 755-767.
17. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association. (2007). Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115 (1), 114-126.
18. Chuengsamarn S, Rattanamongkolgul S, Sittithumcharee G, Jirawatnotai S. (2016). Association of serum high-sensitivity C-reactive protein with metabolic control and diabetic chronic vascular complications in patients with type 2 diabetes. Diabetes Metab. Syndr., 16, 30141-30142.
19. Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Cherardi G, Gale CP, Batin PD, Ajjan R, Kearney L, Wheatcroft SB, Sapsford RJ, Witte KK, Kearney MT. (2013). Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemicaetiology. Diab. Vasc. Dis. Res., 10 (4), 330-336.
20. Deedwania PC. (2003). Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. Am. J. Cardiol., 91 (1), 68-71.
21. Dinarello CA. (2006). Interleukin 1 beta and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr., 83 (2), 447-455.
22. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). (2001). JAMA, 285, 2486-2497.
23. Galis ZS, Sukhova GK, Lark MW, Libby P. (1994). Increased expression of matrix matalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerosis plaques. J. Clin. Invest., 94 (6), 2493-2503.
24. Garcia C, Feve B, Ferré P, Halimi S, Baizri H, Bordier L, Guiu G, Dupuy O, Bauduceau B, Mayaudon H. (2010). Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab., 36 (5), 327-338.
25. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, Crouse JR 3rd, Friedman L, Fuster V, Herrington DM, Kuller LH, Ridker PM, Roberts WC, Stanford W, Stone N, Swan HJ, Taubert KA, Wexler L. (2000). Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation, 101, 16-22.
26. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA (1992) The metabolic profile of NIDDM is fully established in glucose tolerant offspring of two Mexican-American NIDDM parents. Diabetes, 41, 1575-1586.
27. Haffner SM, Mykkänen L, Valdez RA, Stern MP, Holloway DL, Monterrosa A, Bowsher RR. (1994). Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J. Clin. Endocrinol. Metab., 79, 1806-1810.
28. Hotamisligil GS. (2006). Inflammation and metabolic disorders. Nature, 444 (7121), 860-867.
29. IDF Diabetes Atlas, 7th ed. (2015). Available at: http://www.diabetesatlas.org/resources/2015-atlas.html.
30. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. (2002). Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes, 51, 3020-3024.
31. Jialal I, Devaraj S, Venugopal SK. (2004). C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension, 44, 6-11.
32. Kendall M, Sobel BE, Coulston AM. (2003). The insulin resistance syndrome and coronary artery disease. Coron. Artery. Dis., 14 (4), 335-348.
33. Lautamäki R, Airaksinen KE, Seppänen M, Toikka J, Luotolahti M, Ball E, Borra R, Härkönen R, Iozzo P, Stewart M, Knuuti J, Nuutila P. (2005). Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. Diabetes, 54, 2787-2794.
34. Lee AY, Chung SS. (1999). Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J., 13, 23-30.
35. Maggioni AP, Anand I, Gottlieb SO. (2002). Effects of valsarían on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J. Am. Coll. Cardiol., 40, 1414-1421.
36. Miyamoto S, Rubio M, Sussman MA. (2009). Nuclear and mitochondrial signalling Akts in cardiomyocytes. Cardiovasc. Res., 1, 272-285.
37. Muris DM, Houben AJ, Kroon AA, Henry RM, van der Kallen CJ, Sep SJ, Koster A, Dagnelie PC, Schram MT, Stehouwer CD. (2014). Age, waist circumference and blood pressure are associated with skin microvascular flow motion: the Maastricht Study. J. Hypertens., 32 (12), 2439-2449.
38. Orchard TJ, Costacou T, Kretowski A, Nesto RW. (2006). Type 1 diabetes and coronary artery disease. Diabetes Care, 11, 2528-2538.
39. Prentki M, Nolan CJ. (2006). Islet β cell failure in type 2 diabetes. J. Clin. Invest., 116 (7), 1802-1812.
40. Ramana KV, Friedrich B, Tammali R, West MB, Bhatnagar A, Srivastava SK. (2005). Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes, 54, 818-829.
41. Reaven GM. (1998). Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
42. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. (2000). Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 101, 1767-1772.
43. Schauer IE, Shell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, Revers M. (2011). Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes, 1, 306-314.
44. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D’Agostino RB Sr, Fox CS, Larson MG, Murabito JM, O’Donnell CJ, Vasan RS, Wolf PA, Levy D. (2007). The third generation cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. Am. J. Epidemiol., 165, 1328-1335.
45. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. BMJ, 321, 405-412.
46. Tappia PS, Dent MR, Dhalla NS. (2006). Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic. Biol. Med., 41, 349-361.
47. Taubert D, Rosenkranz A, Berkels R, Roesen R, Schmig E. (2004). Acute effects of glucose and insulin on vascular endothelium. Diabetologia, 47, 2059-2071.
48. Uptitchard JE, Sutherland WH, Mann JI. (2000). Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Сare, 23, 733-738.
49. Yilmaz MB, Guray U, Guray Y, Altay H, Demirkan B, Caldir V, Cay S, Refiker ME, Sasmaz H, Korkmaz S. (2005). Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes. Coron. Artery Dis., 100, 561-562.
50. Young J, Libby P, Schonbeck U. (2002). Cytokines in the pathogenesis of atherosclerosis. Thrombos. Haemostas., 88, 554-567.
